Pfizer says product recall only due to incorrect declaration

MANILA, Philippines - Pharmaceutical giant Pfizer Consumer Health yesterday assured the public that the recall of Carbocisteine (Loviscol) 50 mg/mL syrup (oral drops) has nothing to do with the efficacy of the medicine.

In a statement, Pfizer said the recall was due to “incorrect concentration declaration on one side panel of the label” and there was “no issue with the medicine itself or the main dosage instructions and poses no safety risk to consumers.”

“This recall is a measure undertaken by our company in coordination with the Philippine Food and Drug Administration (FDA) in relation to an incorrect concentration declaration on one side panel of both the carton and the bottle labels. The main panel of both the carton and bottle contains the correct declaration of the Carbocisteine concentration,” Pfizer said.

The company added the recall “does not affect any other Loviscol variants (i.e., Loviscol syrup, Loviscol capsule).”

“Pfizer Consumer Healthcare places the utmost emphasis on patient safety and product quality. The company has in place a rigorous quality system to ensure that materials are produced in accordance with all applicable Pfizer and regulatory standards,” it said.

Pfizer also gave assurance that “all future products will carry the correct concentration declaration.”